-

Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2025 Gallup Exceptional Workplace Award (GEWA), marking the second year in a row the company has received this prestigious recognition. This award recognizes the most engaged workplace cultures in the world.

Gallup created the Exceptional Workplace Award to identify excellence and celebrate organizations that incorporate employee engagement into the bedrock of how they do their work, motivate their teams, and achieve business outcomes.

"Exact Sciences’ success starts with our people, and winning the Gallup Exceptional Workplace Award for the second consecutive year is a testament to the dedication of our incredible team," said Sarah Condella, executive vice president of human resources at Exact Sciences. "Our culture is built on shared values, collaboration, and a relentless commitment to our mission. By fostering an environment where employees feel engaged, supported, and empowered, we continue to make a meaningful impact on patients and advance our fight against cancer."

The GEWA winners’ ratio of engaged employees to actively disengaged employees is 11 times higher than the global average. Worldwide, only 23% of employees are engaged — that is, committed to their work and connected to their workplace — and just 33% of employees in the U.S. workforce are engaged. Seventy percent of employees at winning GEWA organizations are engaged.

“Congratulations to this year’s Gallup Exceptional Workplace Award winners for setting the standard for a thriving workplace. Your commitment to creating an environment where employees feel valued, heard and empowered to do their best work is truly remarkable. By prioritizing both people and performance, you are shaping the future of work and proving that exceptional workplaces drive real results,” said Jon Clifton, Gallup’s chief executive officer.

Gallup’s meta-analysis on team engagement and performance is the most comprehensive workplace study ever conducted, with data on more than 3.3 million employees in 347 organizations across 53 industries and 90 countries. The company’s research shows that highly engaged organizations significantly outperform their peers in important business outcomes, including customer ratings, profitability, productivity, turnover, safety incidents, shrinkage, absenteeism, quality, well-being, and organizational citizenship.

For a complete list of GEWA winners and more about the selection process, visit the winners page.

Exact Sciences is looking for talented people who are passionate about helping patients and fighting cancer. For more information and to view a complete list of job openings, visit the company’s careers site.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

About Gallup

Gallup delivers analytics and advice to help leaders and organizations solve their most pressing problems. Combining more than 80 years of experience with its global reach, Gallup knows more about the attitudes and behaviors of employees, customers, students, and citizens than any other organization in the world.

Contacts

Exact Sciences
Blair Brophy
bbrophy@exactsciences.com
608-630-7391

Gallup
media@gallup.com

Exact Sciences Corp.

NASDAQ:EXAS

Release Versions

Contacts

Exact Sciences
Blair Brophy
bbrophy@exactsciences.com
608-630-7391

Gallup
media@gallup.com

More News From Exact Sciences Corp.

Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced new data to be presented from the Beta-CORRECT clinical validation study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Results from Beta-CORRECT, a subset of the GALAXY cohort, validate the performance of its tumor-informed molecular residual disease (MRD) test, Oncodetect™, in predicting recurrence in stage II–IV colorectal...

Exact Sciences to Participate in June Investor Conference

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. William Blair 45th Annual Growth Stock Conference, Chicago Presentation on Tuesday, June 3, 2025 at 9:40 a.m. ET The webcast can be accessed in the investor relations section of Exact Sciences’ website at www.exactsciences.com. About E...

Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30–June 3, 2025, in Chicago, Ill. Presentations include new data on the Oncodetect™ molecular residual disease (MRD) test, multi-cancer early detection (MCED) testing, the Oncotype DX Breast Recurrence Score® test, and the Cologuard®...
Back to Newsroom